Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC 50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with K d of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC 50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC 50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > β-catenin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.